文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

间充质基质细胞修复COVID-19相关急性呼吸窘迫综合征(REALIST-COVID试验):多中心随机对照临床试验

Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial): A Multicenter, Randomized, Controlled Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01
一句话结论在COVID-19相关中重度ARDS患者中,ORBCEL-C间充质基质细胞安全但未改善第7天氧合指数等肺器官功能障碍替代指标。

REALIST-COVID为多中心、随机、双盲、分配隐藏、安慰剂对照试验(NCT03042143),纳入COVID-19相关中重度ARDS患者,随机接受ORBCEL-C(4亿个细胞)或安慰剂(Plasma-Lyte 148)。主要安全终点严重不良事件发生率两组无显著差异(风险比2.9,95%CI 0.6-13.2;P=0.25);主要疗效终点第7天氧合指数无差异(ORBCEL-C组98.3[57.2] cm H2O/kPa vs 安慰剂组96.6[67.3] cm H2O/kPa)。次要替代结局、第28天/90天/1年/2年死亡率、1年间质性肺病患病率及2年内重大医学事件均无差异。ORBCEL-C调节了外周血转录组。

要点

  • ORBCEL-C组6例、安慰剂组3例发生严重不良事件,风险比2.9(95%CI 0.6-13.2),P=0.25,安全性无显著差异。
  • 第7天氧合指数ORBCEL-C组98.3(57.2)cm H2O/kPa vs 安慰剂组96.6(67.3)cm H2O/kPa,无差异。
  • 呼吸顺应性、驱动压、PaO2:FiO2比值、SOFA评分等次要替代结局均无差异。
  • 第28天、第90天、1年、2年死亡率及1年间质性肺病患病率、2年内重大医学事件均无差异。
  • ORBCEL-C调节了外周血转录组,但未转化为肺器官功能障碍替代指标的改善。

适用人群与场景

  • 中重度COVID-19相关急性呼吸窘迫综合征患者。

处置流程与药物剂量

  • ORBCEL-C(CD362富集的人脐带来源间充质基质细胞)4亿个细胞静脉输注;对照组给予安慰剂Plasma-Lyte 148。

研究设计与关键结果

  • 研究类型:多中心、随机、双盲、分配隐藏、安慰剂对照临床试验(NCT03042143)。
  • 样本量:招募60例,最终分析ORBCEL-C组30例、安慰剂组29例(安慰剂组1例撤回知情同意)。
  • 主要安全终点:ORBCEL-C组6例、安慰剂组3例发生严重不良事件,风险比2.9(95%CI 0.6-13.2),P=0.25。
  • 主要疗效终点:第7天氧合指数ORBCEL-C组98.3(57.2)cm H2O/kPa vs 安慰剂组96.6(67.3)cm H2O/kPa,无差异。
  • 次要替代结局(呼吸顺应性、驱动压、PaO2:FiO2比值、SOFA评分)无差异。
  • 第28天、第90天、1年、2年死亡率无差异;1年间质性肺病患病率及2年内重大医学事件无差异。
  • ORBCEL-C调节了外周血转录组(第0、4、7天全血转录组分析)。

证据类型、等级与局限

  • 证据类型:多中心随机双盲安慰剂对照临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为ORBCEL-C间充质基质细胞在中重度COVID-19相关ARDS患者中安全,但未改善肺器官功能障碍替代指标。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Mesenchymal stromal cells (MSCs) may modulate inflammation, promoting repair in coronavirus disease (COVID-19)-related acute respiratory distress syndrome (ARDS). Objectives: We investigated the safety and efficacy of ORBCEL-C (CD362 [cluster of differentiation 362]-enriched, umbilical cord-derived MSCs) in COVID-19-related ARDS. Methods: In this multicenter, randomized, double-blind, allocation-concealed, placebo-controlled trial (NCT03042143), patients with moderate to severe COVID-19-related ARDS were randomized to receive ORBCEL-C (400 million cells) or placebo (Plasma-Lyte 148). The primary safety and efficacy outcomes were the incidence of serious adverse events and oxygenation index at Day 7, respectively. Secondary outcomes included respiratory compliance, driving pressure, PaO2:FiO2 ratio, and Sequential Organ Failure Assessment score. Clinical outcomes relating to duration of ventilation, lengths of ICU and hospital stays, and mortality were collected. Long-term follow-up included diagnosis of interstitial lung disease at 1 year and significant medical events and mortality at 2 years. Transcriptomic analysis was performed on whole blood at Days 0, 4, and 7. Measurements and Main Results: Sixty participants were recruited (final analysis: n = 30 received ORBCEL-C, n = 29 received placebo; 1 participant in the placebo group withdrew consent). Six serious adverse events occurred in the ORBCEL-C group and three in the placebo group (risk ratio, 2.9 [95% confidence interval, 0.6-13.2]; P = 0.25). Day 7 mean (SD) oxygenation index did not differ (ORBCEL-C, 98.3 [57.2] cm H2O/kPa; placebo, 96.6 [67.3] cm H2O/kPa). There were no differences in secondary surrogate outcomes or in mortality at Day 28, Day 90, 1 year, or 2 years. There was no difference in the prevalence of interstitial lung disease at 1 year or significant medical events up to 2 years. ORBCEL-C modulated the peripheral blood transcriptome. Conclusion: ORBCEL-C MSCs were safe in subjects with moderate to severe COVID-19-related ARDS but did not improve surrogates of pulmonary organ dysfunction.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Gorman EA, Rynne J, Gardiner HJ, et al. Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial): A Multicenter, Randomized, Controlled Clinical Trial. Am J Respir Crit Care Med. 2023. PMID: 37154608. doi:10.1164/rccm.202302-0297OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。